Business context and reporting period
Entity: The supplied filing is Inotek Pharmaceuticals Corporation’s unaudited Form 10-Q for the quarter ended September 30, 2016, not a filing identified as Rocket Pharmaceuticals, Inc. Verify the issuer before relying on this summary.
Inotek was a clinical-stage ophthalmology company developing trabodenoson as a glaucoma monotherapy and in a fixed-dose combination (FDC) with latanoprost. It had no approved products and generated no product revenue.
Financial performance and position
Amounts below are in U.S. dollars; financial statement amounts were reported in thousands.
- Revenue: None. The company did not expect product revenue in the near term.
- Third quarter 2016: Operating expenses were $10.7 million, including R&D of $8.4 million and G&A of $2.3 million. Net loss was $11.1 million, or $0.41 per share, versus a $56.0 million loss, or $2.48 per share, in Q3 2015.
- First nine months 2016: Operating expenses were $29.6 million (R&D $22.5 million; G&A $7.1 million). Net loss was $29.9 million, or $1.12 per share, compared with a $59.8 million loss, or $3.85 per share, in the comparable 2015 period.
- Cash flow: Nine-month operating cash use was $26.1 million, investing cash use was $23.8 million, and financing provided $52.9 million. Cash and cash equivalents increased $3.0 million during the period.
- Liquidity: At September 30, 2016, cash and cash equivalents were $83.0 million and short-term investments were $54.6 million, totaling $137.6 million. Current liabilities were $5.9 million.
- Debt: In August 2016, the company issued $52.0 million of unsecured 5.75% convertible senior notes due 2021, receiving approximately $48.7 million net. Their balance-sheet carrying value was $48.8 million after issuance costs. Contractual principal and interest obligations were reported as $67.0 million.
- Margins: Not meaningful because the company had no product revenue.
Material changes versus the prior comparable period
- Q3 R&D expense rose $4.8 million year over year, mainly from ongoing Phase 3 monotherapy and newly initiated Phase 2 FDC trials, increased staffing, and preclinical work. Nine-month R&D expense increased $15.9 million.
- Operating cash use increased from $10.4 million to $26.1 million for the nine-month periods, reflecting expanded development activity.
- Net loss was lower than in 2015, but primarily because 2015 included large noncash charges tied to the conversion and fair-value remeasurement of the 2020 convertible notes, plus debt extinguishment losses. The 2016 loss does not indicate improved operating profitability.
- The company raised capital through the new 2021 notes and received $4.0 million net from ATM share sales during the first nine months. No ATM shares were sold in Q3; $45.6 million remained available under the ATM at quarter-end.
Outlook, commentary, and risks
- Management estimated existing cash and investments would fund operations into mid-2018. This is a forward-looking estimate dependent on trial costs, enrollment, regulatory requirements, and other assumptions; additional financing may be needed.
- Enrollment in the first Phase 3 trabodenoson monotherapy trial was completed in August 2016. Top-line results were expected by late 2016. The Phase 2 FDC dose-ranging trial began in July 2016, with data expected in 2017.
- Management expected R&D and G&A expenses to rise as trials, staffing, and public-company infrastructure expanded. Further capital raising could dilute shareholders or involve restrictive debt terms.
- Key risks include clinical efficacy and safety outcomes, regulatory delays or requests for additional studies, reliance on third-party manufacturers and trial providers, manufacturing scale-up and FDC stability, competition from established and generic glaucoma therapies, reimbursement and market acceptance, and the need for additional funding.
- In October 2016, former Chief Scientific Officer William McVicar entered a transition arrangement: advisor service through April 4, 2017, followed by 12 months of salary and benefits. The company expected aggregate payments of approximately $0.75 million.
- The company reported no current legal proceedings, no off-balance-sheet arrangements, and effective disclosure controls as of September 30, 2016.
Important facts for investors to verify
- Confirm the issuer: the filing names Inotek Pharmaceuticals Corporation, while the request identifies Rocket Pharmaceuticals, Inc.
- Check the actual timing and results of the expected late-2016 Phase 3 readout and 2017 FDC data, and any subsequent regulatory or trial developments.
- Assess the assumptions underlying the mid-2018 cash runway against subsequent cash burn, financing, and clinical-development spending.
- Review the 2021 notes’ conversion, interest, repurchase, and covenant terms, as well as potential dilution and future ATM issuance.
- Confirm the final costs and terms of the former Chief Scientific Officer’s transition arrangement.